Human herpesvirus 8 (Kaposi's sarcoma-associated herpesvirus) infection in men receiving treatment for HIV-1 infection.

Important note: Information in this article was accurate in 2000. The state of the art may have changed since the publication date.

Human herpesvirus 8 (Kaposi's sarcoma-associated herpesvirus) infection in men receiving treatment for HIV-1 infection.

J Acquir Immune Defic Syndr. 1999 Dec 1;22(4):333-40. Unique Identifier : AIDSLINE MED/20097660
Campbell TB; Fitzpatrick L; MaWhinney S; Zhang X; Schooley RT; Department of Medicine, University of Colorado Health Sciences; Center, Denver 80262, USA.

Abstract: OBJECTIVE: To determine the prevalence of human herpesvirus 8 (HHV-8) infection in men treated for HIV-1 infection in Denver, Colorado. DESIGN: Cross-sectional analysis METHODS: Blood samples were obtained from 216 HIV-1-infected men. Antibody to latency-associated nuclear antigen (LANA) was detected by an immunofluorescent assay and the presence of HHV-8 in peripheral blood mononuclear cells (PBMC) was detected by polymerase chain reaction amplification. RESULTS: Among HIV-1-infected men who did not have Kaposi's sarcoma (KS), prevalence of HHV-8 infection was 46% (95% confidence interval [CI], 0.39-0.52). LANA seropositivity was common both among subjects with KS and subjects without KS (69% versus 42%; p = .06), but detection of HHV-8 DNA in peripheral blood was strongly associated with a diagnosis of KS (44% versus 10%; p = .001). In a univariate analysis of study subjects without KS, neither the odds of LANA seropositivity nor detection of HHV-8 DNA in PBMC was significant for CD4+ lymphocyte count, HIV-1 virus load, the use of three drug antiretroviral regimens or the prior occurrence of non-KS AIDS-related conditions. CONCLUSION: Although antibodies to HHV-8 are common among HIV-1-infected men, detection of HHV-8 DNA in PBMC is uncommon and is associated with a diagnosis of Kaposi's sarcoma.

Keywords: JOURNAL ARTICLE Adult Anti-HIV Agents/THERAPEUTIC USE Antibodies, Viral/BLOOD AIDS-Related Opportunistic Infections/*EPIDEMIOLOGY/VIROLOGY Cross-Sectional Studies DNA, Viral/BLOOD Fluorescent Antibody Technique Herpesviridae Infections/*EPIDEMIOLOGY/VIROLOGY Herpesvirus, Kaposi Sarcoma-Associated/GENETICS/IMMUNOLOGY/ *ISOLATION & PURIF Human HIV Infections/COMPLICATIONS/*DRUG THERAPY/VIROLOGY *HIV-1/ISOLATION & PURIF Male Middle Age Nuclear Proteins/IMMUNOLOGY Polymerase Chain Reaction Prevalence Support, Non-U.S. Gov't Support, U.S. Gov't, P.H.S. Viral Load

000430
A0040860

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Elton John AIDS Foundation, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2000. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2000. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .